Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2019-09, Vol.20 (18), p.4624 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 18 |
| container_start_page | 4624 |
| container_title | International journal of molecular sciences |
| container_volume | 20 |
| creator | Abolarinwa, Bilikis Aderonke Ibrahim, Ridwan Babatunde Huang, Yen-Hua |
| description | Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers may predict the immunotherapeutic response of GI cancer patients. However, the therapeutic response of patients selected by the predictive biomarkers is suboptimal. The tumor immune-microenvironment apparently plays a key role in modulating these molecular-determinant predictive biomarkers. Therefore, an understanding of the development and recent advances in immunotherapeutic pharmacological intervention targeting tumor immune-microenvironments and their potential predictive biomarkers will be helpful to strengthen patient immunotherapeutic efficacy. The current review focuses on an understanding of how the host-microenvironment interactions and the predictive biomarkers can determine the efficacy of immune checkpoint inhibitors. The contribution of environmental pathogens and host immunity to GI cancer is summarized. A discussion regarding the clinical evidence of predictive biomarkers for clinical trial therapy design, current immunotherapeutic strategies, and the outcomes to GI cancer patients are highlighted. An understanding of the underlying mechanism can predict the immunotherapeutic efficacy and facilitate the future development of personalized therapeutic strategies targeting GI cancers. |
| doi_str_mv | 10.3390/ijms20184624 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6769557</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2346457990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-f26e099528528cb0b4c184f1250a6e8231724111066c59c38028cb791dc761483</originalsourceid><addsrcrecordid>eNpVkd1LwzAUxYMobk7ffJaCr1bz3eZFGFXnYCCCPoc0S11H29QkHfjfm7E5JlzIhfxy7jm5AFwjeE-IgA_1uvUYopxyTE_AGFGMUwh5dnrUj8CF92sIMcFMnIMRQYxCStgYvBe206YPg2qSJ7Mxje1b04XEVsm8bYfOhpVxqjdDqHUy7XtnlV4ZnwSbzJQPztZdMD7UXXxfqCjlLsFZpRpvrvbnBHy-PH8Ur-nibTYvpotUU4RDWmFuoBAM57F0CUuqY4YKYQYVNzkmKMMUIQQ510xoksMtlgm01BlHNCcT8LjT7YeyNUsdXTvVyN7VrXI_0qpa_r_p6pX8shvJMy4Yy6LA7V7A2e8hhpBrO7gYxEtMKKcsEwJG6m5HaWe9d6Y6TEBQbhcgjxcQ8ZtjVwf478fJL1RXgc8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2346457990</pqid></control><display><type>article</type><title>Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Abolarinwa, Bilikis Aderonke ; Ibrahim, Ridwan Babatunde ; Huang, Yen-Hua</creator><creatorcontrib>Abolarinwa, Bilikis Aderonke ; Ibrahim, Ridwan Babatunde ; Huang, Yen-Hua</creatorcontrib><description>Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers may predict the immunotherapeutic response of GI cancer patients. However, the therapeutic response of patients selected by the predictive biomarkers is suboptimal. The tumor immune-microenvironment apparently plays a key role in modulating these molecular-determinant predictive biomarkers. Therefore, an understanding of the development and recent advances in immunotherapeutic pharmacological intervention targeting tumor immune-microenvironments and their potential predictive biomarkers will be helpful to strengthen patient immunotherapeutic efficacy. The current review focuses on an understanding of how the host-microenvironment interactions and the predictive biomarkers can determine the efficacy of immune checkpoint inhibitors. The contribution of environmental pathogens and host immunity to GI cancer is summarized. A discussion regarding the clinical evidence of predictive biomarkers for clinical trial therapy design, current immunotherapeutic strategies, and the outcomes to GI cancer patients are highlighted. An understanding of the underlying mechanism can predict the immunotherapeutic efficacy and facilitate the future development of personalized therapeutic strategies targeting GI cancers.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20184624</identifier><identifier>PMID: 31540435</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - immunology ; Gastrointestinal Neoplasms - diagnosis ; Gastrointestinal Neoplasms - immunology ; Gastrointestinal Neoplasms - therapy ; Humans ; Immunity ; Immunotherapy - methods ; Prognosis ; Review ; Tumor Microenvironment</subject><ispartof>International journal of molecular sciences, 2019-09, Vol.20 (18), p.4624</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-f26e099528528cb0b4c184f1250a6e8231724111066c59c38028cb791dc761483</citedby><cites>FETCH-LOGICAL-c412t-f26e099528528cb0b4c184f1250a6e8231724111066c59c38028cb791dc761483</cites><orcidid>0000-0001-6020-9998</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769557/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769557/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31540435$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abolarinwa, Bilikis Aderonke</creatorcontrib><creatorcontrib>Ibrahim, Ridwan Babatunde</creatorcontrib><creatorcontrib>Huang, Yen-Hua</creatorcontrib><title>Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers may predict the immunotherapeutic response of GI cancer patients. However, the therapeutic response of patients selected by the predictive biomarkers is suboptimal. The tumor immune-microenvironment apparently plays a key role in modulating these molecular-determinant predictive biomarkers. Therefore, an understanding of the development and recent advances in immunotherapeutic pharmacological intervention targeting tumor immune-microenvironments and their potential predictive biomarkers will be helpful to strengthen patient immunotherapeutic efficacy. The current review focuses on an understanding of how the host-microenvironment interactions and the predictive biomarkers can determine the efficacy of immune checkpoint inhibitors. The contribution of environmental pathogens and host immunity to GI cancer is summarized. A discussion regarding the clinical evidence of predictive biomarkers for clinical trial therapy design, current immunotherapeutic strategies, and the outcomes to GI cancer patients are highlighted. An understanding of the underlying mechanism can predict the immunotherapeutic efficacy and facilitate the future development of personalized therapeutic strategies targeting GI cancers.</description><subject>Animals</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - immunology</subject><subject>Gastrointestinal Neoplasms - diagnosis</subject><subject>Gastrointestinal Neoplasms - immunology</subject><subject>Gastrointestinal Neoplasms - therapy</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunotherapy - methods</subject><subject>Prognosis</subject><subject>Review</subject><subject>Tumor Microenvironment</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpVkd1LwzAUxYMobk7ffJaCr1bz3eZFGFXnYCCCPoc0S11H29QkHfjfm7E5JlzIhfxy7jm5AFwjeE-IgA_1uvUYopxyTE_AGFGMUwh5dnrUj8CF92sIMcFMnIMRQYxCStgYvBe206YPg2qSJ7Mxje1b04XEVsm8bYfOhpVxqjdDqHUy7XtnlV4ZnwSbzJQPztZdMD7UXXxfqCjlLsFZpRpvrvbnBHy-PH8Ur-nibTYvpotUU4RDWmFuoBAM57F0CUuqY4YKYQYVNzkmKMMUIQQ510xoksMtlgm01BlHNCcT8LjT7YeyNUsdXTvVyN7VrXI_0qpa_r_p6pX8shvJMy4Yy6LA7V7A2e8hhpBrO7gYxEtMKKcsEwJG6m5HaWe9d6Y6TEBQbhcgjxcQ8ZtjVwf478fJL1RXgc8</recordid><startdate>20190918</startdate><enddate>20190918</enddate><creator>Abolarinwa, Bilikis Aderonke</creator><creator>Ibrahim, Ridwan Babatunde</creator><creator>Huang, Yen-Hua</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6020-9998</orcidid></search><sort><creationdate>20190918</creationdate><title>Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer</title><author>Abolarinwa, Bilikis Aderonke ; Ibrahim, Ridwan Babatunde ; Huang, Yen-Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-f26e099528528cb0b4c184f1250a6e8231724111066c59c38028cb791dc761483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - immunology</topic><topic>Gastrointestinal Neoplasms - diagnosis</topic><topic>Gastrointestinal Neoplasms - immunology</topic><topic>Gastrointestinal Neoplasms - therapy</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunotherapy - methods</topic><topic>Prognosis</topic><topic>Review</topic><topic>Tumor Microenvironment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abolarinwa, Bilikis Aderonke</creatorcontrib><creatorcontrib>Ibrahim, Ridwan Babatunde</creatorcontrib><creatorcontrib>Huang, Yen-Hua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abolarinwa, Bilikis Aderonke</au><au>Ibrahim, Ridwan Babatunde</au><au>Huang, Yen-Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-09-18</date><risdate>2019</risdate><volume>20</volume><issue>18</issue><spage>4624</spage><pages>4624-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Gastrointestinal (GI) cancer is one of the common causes of cancer-related death worldwide. Chemotherapy and/or immunotherapy are the current treatments, but some patients do not derive clinical benefits. Recently, studies from cancer molecular subtyping have revealed that tumor molecular biomarkers may predict the immunotherapeutic response of GI cancer patients. However, the therapeutic response of patients selected by the predictive biomarkers is suboptimal. The tumor immune-microenvironment apparently plays a key role in modulating these molecular-determinant predictive biomarkers. Therefore, an understanding of the development and recent advances in immunotherapeutic pharmacological intervention targeting tumor immune-microenvironments and their potential predictive biomarkers will be helpful to strengthen patient immunotherapeutic efficacy. The current review focuses on an understanding of how the host-microenvironment interactions and the predictive biomarkers can determine the efficacy of immune checkpoint inhibitors. The contribution of environmental pathogens and host immunity to GI cancer is summarized. A discussion regarding the clinical evidence of predictive biomarkers for clinical trial therapy design, current immunotherapeutic strategies, and the outcomes to GI cancer patients are highlighted. An understanding of the underlying mechanism can predict the immunotherapeutic efficacy and facilitate the future development of personalized therapeutic strategies targeting GI cancers.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31540435</pmid><doi>10.3390/ijms20184624</doi><orcidid>https://orcid.org/0000-0001-6020-9998</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2019-09, Vol.20 (18), p.4624 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6769557 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Animals Biomarkers, Tumor - analysis Biomarkers, Tumor - immunology Gastrointestinal Neoplasms - diagnosis Gastrointestinal Neoplasms - immunology Gastrointestinal Neoplasms - therapy Humans Immunity Immunotherapy - methods Prognosis Review Tumor Microenvironment |
| title | Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T07%3A14%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Conceptual%20Development%20of%20Immunotherapeutic%20Approaches%20to%20Gastrointestinal%20Cancer&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Abolarinwa,%20Bilikis%20Aderonke&rft.date=2019-09-18&rft.volume=20&rft.issue=18&rft.spage=4624&rft.pages=4624-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20184624&rft_dat=%3Cproquest_pubme%3E2346457990%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2346457990&rft_id=info:pmid/31540435&rfr_iscdi=true |